



30 July 2021

Exercise of Options

Creso Pharma Limited (ASX:CPH, OTC:COPHF, FRA:1X8) ('Creso Pharma' or 'the Company') advises that it has issued 48,146,347 Ordinary Shares upon exercise of 48,146,347 CPHOA Options (\$0.05, 22 Jan 2023), pursuant to the Appendix 2A released today ("Appendix 2A"), raising \$2,407,317 (before costs).

In addition to the above, the Company advises that 200,000 CPHOPT16 Options (\$0.535, 27 Jul 2021) expired unexercised per the Appendix 3H lodged also today ("Appendix 3H").

Following the above, the issued capital of the Company is as follows:

Type of Securities	Total Number of Securities
<u>Shares</u>	
CPH Ordinary Fully Paid Shares ¹	1,196,563,982
<u>Options</u>	
CPHOA Listed Options (\$0.05, 22/01/2023)	69,648,930
CPHOPT17 Options (\$0.80, 27/07/2022)	200,000
CPHOPT18 Options (\$0.55, 21/08/2021)	200,000
CPHOPT19 Options (\$0.80, 15/09/2022)	300,000
CPHOPT20 Options (\$0.35, 12/02/2023)	2,128,387
CPHOPT21 Options (\$0.40, 12/02/2023)	6,847,725
CPHOPT22 Options (\$0.25, 1/03/2023)	250,000
CPHOPT23 Options (\$0.08, 10/03/2024) ²	1,000,000
CPHOPT24 Options (\$0.16, 10/03/2024) ²	1,000,000
CPHOPT25 Options (\$0.20, 10/03/2024) ²	500,000
CPHOPT26 Options (\$0.1386, 25/06/2023)	5,752,688
CPHOPT28 Options (\$0.17, 2/06/2023)	27,764,706
CPHOPT29 Options (\$0.25, 2/06/2023)	4,000,000
CPHOPT31 Options (\$0.20, 2/06/2023)	8,000,000
CPHOPT32 Options (\$0.20, 23/12/2023)	833,333
CPHOPT33 Options (\$0.039, 23/12/2025)	30,000,000
CPHOPT34 Options (\$0.235, 11/01/2023)	8,000,000
CPHOPT35 Options (\$0.27, 11/01/2023)	8,000,000
CPHOPT36 Options (\$0.30, 11/01/2023)	8,000,000
CPHOPT37 Options (\$0.40, 11/01/2023)	2,800,000
CPHOPT38 Options (\$0.38, 14/07/2024)	12,000,000



Type of Securities	Total Number of Securities
<u>Performance Shares</u> CPHPERSF Performance Shares ³	17,551,077
<u>Performance Rights</u> CPHPERR6 Performance Rights ² CPHPERR7 Performance Rights ²	800,000 800,000
<u>Employee Performance Rights (Under Plan)</u> CPHPERR22 Employee Performance Rights CPHPERR23 Employee Performance Rights CPHPERR24 Employee Performance Rights	33,000 33,000 132,000

1. Includes 29,251,795 voluntarily escrowed shares to 14 January 2022.
2. Subject to performance milestones and/or vesting conditions.
3. Voluntarily escrowed to 14 January 2022.

-Ends-

Authority and Contact Details

This announcement has been authorised for release by Eryln Dale, Joint Company Secretary.

For further information, please contact:

Investor Enquiries

EverBlu Capital
E: info@everblucapital.com
P: +61 2 8249 0000

Released through:

Ben Jarvis, Six Degrees Investor Relations: Ph: +61 (0) 413 150 448

About Creso Pharma

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health.

Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit:

www.cresopharma.com